Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Nos articles
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
The feature you requested does not exist. However, we suggest the following feature:

(ATHA) Alert: Did You Acquire Athira Before November 2020? Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel

10/23/2021 | 02:19pm EDT

SAN DIEGO, Oct. 23, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) against certain of its officers and directors. 

Recently a class action lawsuit was filed in federal court against the Company on behalf of purchasers of the securities of Athira from September 18, 2020 and June 17, 2021 (the "Class Period").

The Athira Pharma class-action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the research conducted by Athira Pharma's President and Chief Executive Officer, defendant Leen Kawas, which formed the foundation for Athira Pharma's product candidates and intellectual property, was tainted by Kawas's scientific misconduct, including the manipulation of key data; and (ii) as a result, defendants' positive statements about Athira Pharma's business, operations, and prospects were materially misleading and omitted material facts necessary to make the statements made not misleading.

If you are a current shareholder of Athira, holding shares before November 2020, you may have standing to hold Athira harmless from the alleged harm caused by the officers and directors of the Company by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. Click here to join this action

If you are interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

Additionally, if you are a current, long-term shareholder of Athira, holding shares before November 2020, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

[Click here to join this action]



© GlobeNewswire 2021
Latest news "Nos articles"
10/22PUMP / DUMP #7 : Watch: This week's gainers and losers
10/22Weekly market update : Investors breathe a sigh of relief
10/22WALL STREET STOCK EXCHANGE : Nasdaq takes a hit from Intel and Snap
10/22ANALYST RECOMMENDATIONS : Ally Financial, Intel, Las Vegas Sands, Tesla, Verizon...
10/22WATCH : Investors 'skeptical' of SPACs, IPOs -analyst
10/22Game of Tesla
10/22The latest from London: Evergrande's surprise payment boosts the FTSE 100
10/21GLOBAL MARKETS LIVE : Tesla, Unilever, Paypal, Elliott, Novartis...
10/21Today on Wall Street: TRUTH will prevail
10/21ANALYST RECOMMENDATIONS : Ford, Hilton, IBM, Johnson & Johnson, Netflix...
Latest news "Nos articles"